BIVI · Biovie Inc.
$2.03
-0.22 (-9.60%)
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-K filed Aug 13, 2026
Market Cap
$17.20M
Shares
7.54M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-12 | Earnings conference call (announced in 8-K) | Earnings call |
| 2026-05-07 | BioVie Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease ahead of Topline Data in 2Q26 | Event |
| 2026-03-04 | RedChip Investor Webinar with BioVie | Event |
| 2025-10-08 | RedChip Investor Webinar with BioVie | Event |
| 2025-05-28 | Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease | Event |
| 2025-04-10 | Long COVID Treatment Landscape & BioVie's ADDRESS-LC Trial: KOL Webcast with Lindsay McAlpine, MD, BSc (Yale University) | Webcast |
| 2023-12-07 | RedChip Webinar | December 7, 2023 | Event |
| 2023-11-29 | Conference Call | November 29, 2023 | Conference |
| 2023-11-01 | Conference Call | November 1, 2023 | Conference |
| 2023-09-26 | Cantor Health Care Conference | Conference |
| 2023-09-07 | Virtual KOL Event | Event |
| 2023-03-23 | BioVie Day 2023 | Event |
Source: https://investors.bioviepharma.com/overview/default.aspx
Key facts
CIK
1580149
CUSIP
09074F504
13F (30d)
38 filings
36 filers
Visit website
Investor relations